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Abstract. The focus of pancreatic cancer research has been shifted from pan-
creatic cancer cells towards their microenvironment, involving pancreatic stellate
cells that interact with cancer cells and influence tumor progression. To quantita-
tively understand the pancreatic cancer microenvironment, we construct a com-
putational model for intracellular signaling networks of cancer cells and stel-
late cells as well as their intercellular communication. We extend the rule-based
BioNetGen language to depict intra- and inter-cellular dynamics using discrete
and continuous variables respectively. Our framework also enables a statistical
model checking procedure for analyzing the system behavior in response to vari-
ous perturbations. The results demonstrate the predictive power of our model by
identifying important system properties that are consistent with existing experi-
mental observations. We also obtain interesting insights into the development of
novel therapeutic strategies for pancreatic cancer.
1 Introduction
Pancreatic cancer (PC), as an extremely aggressive disease, is the seventh leading cause
of cancer death globally [2]. For decades, extensive efforts were made on developing
therapeutic strategies targeting at pancreatic cancer cells (PCCs). However, the poor
prognosis for PC remains largely unchanged. Recent studies have revealed that the fail-
ure of systemic therapies for PC is partially due to the tumor microenvironment, which
turns out to be essential to PC development [11, 13, 14, 23]. As a characteristic feature
of PC, the microenvironment includes pancreatic stellate cells (PSCs), immune cells,
endothelial cells, nerve cells, lymphocytes, dendritic cells, the extracellular matrix, and
other molecules surrounding PCCs, among which, PSCs play key roles during the PC
development [23]. In this paper, to obtain a system-level understanding of the PC mi-
croenvironment, we construct a multicellular model including intracellular signaling
networks of PCCs and PSCs respectively, and intercellular interactions among them.
Boolean Networks (BNs) [35] has been widely used to model biological networks
[3]. A Boolean network is an executable model that characterizes the status of each
biomolecule by a binary variable that related to the abundance or activity of the molecule.
It can capture the overall behavior of a biological network and provide important in-
sights and predictions. Recently, it has been found useful to study the signaling net-
works in PCCs [16, 17]. Rule-based modeling language is another successfully used
formalism for dynamical biological systems, which allows molecular/kinetic details of
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signaling cascades to be specified [9, 12]. It provides a rich yet concise description
of signaling proteins and their interactions by representing interacting molecules as
structured objects and by using pattern-based rules to encode their interactions. The dy-
namics of the underlying system can be tracked by performing stochastic simulations.
In this paper, to formally describe our multicellular and multiscale model, we extend
the rule-based language BioNetGen [12] to enable the formal specification of not only
the signaling network within a single cell, but also interactions among multiple cells.
Specifically, we represent the intercellular level dynamics using rules with continuous
variables and use BNs to capture the dynamics of intracellular signaling networks, con-
sidering the fact that a large number of reaction rate constants are not available in the lit-
erature and difficult to be experimentally determined. Our extension saves the virtues of
both BNs and rule-based kinetic modeling, while advancing the specification power to
multicellular and multiscale models. We employ stochastic simulation NFsim [34] and
statistical model checking (StatMC) [22] to analyze the systems properties. The formal
analysis results show that our model reproduces existing experimental findings with re-
gard to the mutual promotion between pancreatic cancer and stellate cells. The model
also provides insights into how treatments latching onto different targets could lead to
distinct outcomes. Using the validated model, we predict novel (poly)pharmacological
strategies for improving PC treatment.
Related work. Various mathematical formalisms have been used for the cancer
microenvironment modeling (see a recent review [5]). In particular, Gong [15] built a
qualitative model to analyze the intracellular signaling reactions in PCCs and PSCs.
This model is discrete and focuses on cell proliferation, apoptosis, and angiogenesis
pathways. While, our model is able to make quantitative predictions and also considers
pathways regulating the autophagy of PCCs and the activation and migration of PSCs,
as well as the interplay between PCCs and PSCs. In terms of the modeling language,
the ML-Rules proposed by Maus et al. [28] extended BioNetGen to support hierarchical
modeling. It allows users to describe inter- and intra-cellular processes at the cellular
level. ML-Rules uses continuous rate equations to capture the dynamics of intracellular
reactions, and thus requires all the rate constants to be known. Instead, our language
models intracellular dynamics using BNs, which reduces the difficulty of estimating
the values of hundreds of unknown parameters often involved in large models.
The paper is organized as follows. In Section 2, we present the multicellular model
for the PC microenvironment. We then introduce our rule-based modeling formalism
extended from the BioNetGen language in Section 3. In Section 4, we briefly introduce
StatMC that is used to carry out formal analysis of the model. The analysis results are
given and discussed in Section 5. Section 6 concludes the paper.
2 Reaction Network of Pancreatic Cancer Microenvironment
We construct a multicellular model for pancreatic cancer microenvironment based on a
comprehensive literature search. The reaction network of the model is summarized in
Figure 1. It consists of three parts that are colored with green, blue, and purple respec-
tively: (i) the intracellular signaling network of PCCs, (ii) the intracellular signaling net-
work of PSCs, and (iii) the signaling molecules (such as growth factors and cytokines)
in the extracellular space of the microenvironment, which are ligands of the receptors
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expressed in PCCs and PSCs. Note that→ denotes activation/promotion/up-regulation,
and represents inhibition/ suppression/down-regulation.
2.1 The intracellular signaling network of PCCs
Pathways regulating proliferation
KRas mutation enhances proliferation [7]. Mutations of the KRas oncogene oc-
cur in the precancerous stages with a mutational frequency over 90%. It can lead to the
continuous activation of the RAS protein, which then constantly triggers the RAF→MEK
cascade, and promotes PCCs’ proliferation through the activation of ERK and JNK.
EGF activates and enhances proliferation [30]. Epidermal growth factor (EGF)
and its corresponding receptor (EGFR) are expressed in ∼95% of PCs. EGF promotes
proliferation through the RAS→RAF→MEK→JNK cascade. It can also trigger the
RAS→RAF→MEK→ERK→cJUN cascade to secrete EGF molecules, which can then
quickly bind to overexpressed EGFR again to promote PCC proliferation, which is be-
lieved to confer the devastating nature on PCs.
HER2/neu mutation also intensifies proliferation [7]. HER2/neu is another onco-
gene frequently mutated in the initial PC formation. Mutant HER2 can bind to EGFR to
form a heterodimer, which can activate the downstream signaling pathways of EGFR.
bFGF promotes proliferation [8]. As a mitogenic polypeptide, bFGF can promote
proliferation through both RAF→MEK→ERK and RAF→MEK→JNK cascades. In
addition, bFGF molecules are released through RAF→MEK→ERK pathway to trigger
another autocrine signaling pathway in the PC development.
Pathways regulating apoptosis
Apoptosis is the most common mode of programmed cell death. It is executed by
caspase proteases that are activated by death receptors or mitochondrial pathways.
TGFβ1 initiates apoptosis [33]. In PCCs, transforming growth factor β 1 (TGFβ1)
binds to and activates its receptor (TGFR), which in turn activates receptor-regulated
SAMDs that hetero-oligomerize with the common SAMD3 and SAMD4. After translo-
cating to the nucleus, the complex initiates apoptosis in the early stage of the PC devel-
opment.
Mutated oncogenes inhibit apoptosis. Mutated KRas and HER2/neu can inhibit
apoptosis by downregulating caspases (CASP) through PI3K→AKT→NFκB cascade
and by inhibiting Bax (and indirectly CASP) via PI3K→PIP3→AKT→· · ·→BCL-XL
pathways.
Pathways regulating autophagy
Autophagy is a catabolic process involving the degradation of a cell’s own com-
ponents through the lysosomal machinery. This pro-survival process enables a starving
cell to reallocate nutrients from unnecessary processes to essential processes. Recent
studies indicate that autophagy is important in the regulation of cancer development and
progression and also affects the response of cancer cells to anticancer therapy [19, 24].
mTOR regulates autophagy [29]. The mammalian target of rapamycin (mTOR) is
a critical regulator of autophagy. In PCCs, the upstream pathway PI3K→PIP3→AKT
activates mTOR and inhibits autophagy. The MEK→ERK cascade downregulates mTOR
via cJUN and enhances autophagy.
Overexpression of anti-apoptotic factors promotes autophagy [26]. Apoptosis
and autophagy can mutually inhibit each other due to their crosstalks. In the initial
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Fig. 1: The pancreatic cancer microenvironment model
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stage of PC, the upregulation of apoptosis leads to the inhibition of autophagy. Along
with the progression of cancer, when apoptosis is suppressed by the highly expressed
anti-apoptotic factors (e.g. NFκB and Beclin1), autophagy gradually takes the dominant
role and promotes PCC survival.
2.2 Intracellular signaling network of PSCs
Pathways regulating activation
PCCs can activate the surrounding inactive PSCs by cancer-cell-induced release of
mitogenic and fibrogenic factors, such as PDGFBB, TGFβ1, and TNFα. As a major
growth factor regulating the cell functions of PSCs, PDGFBB activates PSCs [18]
through the downstream ERK→AP1 signaling pathway. The activation of PSCs is
also mediated by TGFβ1 [18] via TGFR→SAMD pathway. The autocrine signaling
of TGFβ1 maintains the sustained activation of PSCs. Furthermore, the cytokine TNFα
is also involved in activating PSCs [27] through binding to TNFR, which indirectly
activates NFκB.
Pathways regulating migration
Migration is another characteristic cell function of PSCs. Activated PSCs move
towards PCCs, and form a cocoon around tumor cells, which could protect the tumor
from therapies’ attacks [6, 14].
Growth factors promote migration. Growth factors existing in the microenviron-
ment, including EGF, bFGF, and VEGF, can bind to their receptors on PSCs and activate
the migration through the MAPK pathway.
PDGFBB contributes to the migration [31]. PDGFBB regulates the migration
of PSCs mainly through two downstream pathways: (i) the PI3K→PIP3→AKT path-
way, which mediates PDGF-induced PSCs’ migration, but not proliferation, and (ii) the
ERK→AP1 pathway that regulates activation, migration, and proliferation of PSCs.
Pathways regulating proliferation
Growth factors activate proliferation. In PSCs, as key downstream components
for several signaling pathways initiated by distinct growth factors, such as EGF and
bFGF, the ERK→AP1 cascade activates the proliferation of PSCs. Compared to inactive
PSCs, active ones proliferate more rapidly.
Tumor suppressers repress proliferation. Similar to PCCs, P53, P21, and PTEN
act as suppressers for PSCs’ proliferation.
Pathways regulating apoptosis
P53 upregulates modulator of apoptosis [21]. The apoptosis of PSCs can be ini-
tiated by P53. The expression of p53 is regulated by the MAPK pathway.
2.3 Interactions between PCCs and PSCs
The mechanism underlying the interplay between PCCs and PSCs is complex. In a
healthy pancreas, PSCs exist quiescently in the periacinar, perivascular, and periductal
space. However, in the diseased state, PSCs will be activated by growth factors, cy-
tokines, and oxidant stress secreted or induced by PCCs, including EGF, bFGF, VEGF,
TGFβ1, PDGF, sonic hedgehog, galectin 3, endothelin 1 and serine protease inhibitor
nexin 2 [10]. Activated PSCs will then transform from the quiescent state to the my-
ofibroblast phenotype. This results in their losinlipid droplets, actively proliferating,
migrating, producing large amounts of extracellular matrix, and expressing cytokines,
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chemokines, and cell adhesion molecules. In return, the activated PSCs promote the
growth of PCCs by secreting various factors, including stromal-derived factor 1, FGF,
secreted protein acidic and rich in cysteine, matrix metalloproteinases, small leucine-
rich proteoglycans, periostin and collagen type I that mediate effects on tumor growth,
invasion, metastasis and resistance to chemotherapy [10]. Among them, EGF, bFGF,
VEGF, TGFβ1, and PDGFBB are essential mediators of the interplay between PCCs
and PSCs that have been considered in our model.
Autocrine and paracrine involving EGF/bFGF [25]. EGF and bFGF can be se-
creted by both PCCs and PSCs. In turn, they will bind to EGFR and FGFR respectively
on both PCCs and PSCs to activate their proliferation and further secretion of EGF and
FGF.
Interplay through VEGF [38]. As a proangiogenic factor, VEGF is found to be
of great importance in the activation of PSCs and angiogenesis during the progres-
sion of PCs. VEGF, secreted by PCCs, can bind with VEGFR on PSCs to activate the
PI3K pathway. It further promotes the migration of PSCs through PIP3→AKT, and
suppresses the transcription activity of P53 via MDM2.
Autocrine and paracrine involving TGFβ1 [25]. PSCs by themselves are capable
of synthesizing TGFβ1, suggesting the existence of an autocrine loop that may con-
tribute to the perpetuation of PSC activation after an initial exogenous signal, thereby
promoting the development of pancreatic fibrosis.
Interplay through PDGFBB [10]. PDGFBB exists in the secretion of PCCs, whose
production is regulated by TGFβ1 signaling pathway. PDGFBB can activate PSCs and
initiate migration and proliferation as well.
3 The Modeling Language
Rule-based modeling languages are often used to specify protein-to-protein reactions
within cells and to capture the evolution of protein concentrations. BioNetGen lan-
guage is a representative rule-based modeling formalism [12], which consists of three
components: basic building blocks, patterns, and rules. In our setting, in order to simul-
taneously simulate the dynamics of multiple cells, interactions among cells, and intra-
cellular reactions, we advance the specifying power of BioNetGen by redefining basic
building blocks and introducing new types of rules for cellular behaviors as follows.
Basic building blocks. The basic building blocks in BioNetGen are molecules
that may be assembled into complexes through bonds linking components of differ-
ent molecules. To handle multiscale dynamics (i.e. cellular and molecular levels), we
allow the fundamental blocks to be also cells or extracellular molecules. Specifically, a
cell is treated as a fundamental block with subunits corresponding to the components
of its intracellular signaling network. Furthermore, extracellular molecules (e.g. EGF)
are treated as fundamental blocks without subunits.
Since we use BNs to model intracellular signaling networks, each subunit of a
cell takes binary values (it is straightforward to extend BNs to discrete models). The
Boolean values - “True (T)” and “False (F)” - can have different biological meanings
for distinct types of components within the cell. For example, for a subunit represent-
ing cellular process (e.g. apoptosis), “T” means the cellular process is triggered, and
“F” means it is not triggered. For a receptor, “T” means the receptor is bound, and “F”
means it is free. For a protein, “T” indicates this protein has a high concentration, and
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“F” indicates that its concentration level is below the value to regulate the downstream
targets.
Patterns. As defined in BioNetGen, patterns are used to identify a set of species that
share features. For instance, the patternC(c1) matches bothC(c1, c2 ∼ T ) andC(c1, c2 ∼
F). Using patterns offers a rich yet concise description in specifying components.
Rules. In BioNetGen, three types of rules are used to specified: binding/unbinding,
phosphorylation, and dephosphorylation. Here we introduce nine rules in order to de-
scribe the cellular processes in our model and the potential therapeutic interventions.
For each type of rules, we present its formal syntax followed by examples that demon-
strate how it is used in our model.
Rule 1: Ligand-receptor binding
< Lig > + < Cell > (< Rec >∼ F)→< Cell > (< Rec >∼ T ) < binding rate >
Remark: On the left-hand side, the “F” value of a receptor < Rec > indicates that
the receptor is free. When a ligand < Lig > binds to it, the reduction of number of
extracellular ligand is represented by its elimination. In the meanwhile, “< Rec >∼ T”,
on the right-hand side, indicates that the receptor is not free any more. Note that, the
multiple receptors on the surface of a cell can be modeled by setting a relatively high
rate on the following downstream regulating rules, which indicates the rapid “releasing”
of bound receptors. An example in our microenvironment model is the binding between
EGF and EGFR for PCCs: “EGF + PCC(EGFR ∼ F)→ PCC(EGFR ∼ T ) 1”.
Rule 2: Mutated receptors form a heterodimer
< Cell > (< Rec1 >∼ F, < Rec2 >∼ F)→
< Cell > (< Rec1 >∼ T, < Rec2 >∼ T ) < mutated binding rate >
Remark: Unbound receptors can bind together and form a heterodimer. For example, in
our model, the mutated HER2 can activate downstream pathways of EGFR by binding
with it and forming a heterodimer: “’PCC(EGFR ∼ F,HER2 ∼ F) → PCC(EGFR ∼
T,HER2 ∼ T ) 10”.
Rule 3: Downstream signaling transduction
Rule 3.1 (Single parent) upregulation (activation, phosphorylation, etc.)
< Cell > (< Act >∼ T, < Tar >∼ F)→< Cell > (< Act >∼ T, < Tar >∼ T ) < trate >
Rule 3.2 (Single parent) downregulation (inhibition, dephosphorylation, etc.)
< Cell > (< Inh >∼ T, < Tar >∼ T )→< Cell > (< Inh >∼ T, < Tar >∼ F) < trate >
Rule 3.3 (Multiple parents) Downstream regulation
< Cell > (< Inh >∼ F, < Act >∼ T, < Tar >∼ F)→
< Cell > (< Inh >∼ F, < Act >∼ T, < Tar >∼ T ) < trate >
< Cell > (< Inh >∼ T, < Tar >∼ T )→< Cell > (< Inh >∼ T, < Tar >∼ F) < trate >
Remark: Instead of using kinetic rules (such as in ML-Rules), our language use logical
rules of BNs to describe intracellular signal cascades. Downsteam signal transduction
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rules are used to describe the logical updating functions for all intracellular molecules
constructing the signaling cascades. For instance, Rule 3.3 presents the updating func-
tion < Tar >(t+1)= ¬ < Inh >(t) ×(< Act >(t)+ < Tar >(t)), where “< Inh >” is the
inhibitor, and “< Act >” is the activator. In this manner, concise rules can be devised
to handle complex cases, where there exists multiple regulatory parents. Note that our
model follows the biological assumption that inhibitors hold higher priorities than acti-
vators with respect to their impacts on the target. “+” and “×” in logical functions repre-
sent logical “OR” and “AND” respectively. An example in our model is that, in PCCs,
STAT can be activated by JAK1: “PCC(JAK1 ∼ T, STAT ∼ T ) → PCC(JAK1 ∼
F, STAT ∼ T ) 0.012” and “PCC(JAK1 ∼ T, STAT ∼ F) → PCC(JAK1 ∼
F, STAT ∼ T ) 0.012”.
Rule 4: Cellular processes
Rule 4.1 Proliferation
< Cell > (Pro ∼ T )→< Cell > (Pro ∼ F)+ < Cell > (Pro ∼ F, · · · ) < pro rate >
Remark: When a cell proliferates, we keep the current values of subunits for the cell
that initiates the proliferation, and assume the new cell to have the default values of
subunits. The “· · · ” in the rule denotes the remaining subunits with their default values.
Rule 4.2 Apoptosis
< Cell > (Apo ∼ T )→ Null() < apop rate >
Remark: A type “Null()” is declared to represent dead cells or degraded molecules. In
our model, the apoptosis of PSCs is described as “PSC(Apo ∼ T )→ Null() 5e − 4”.
Rule 4.3 Autophagy
< Cell > (Aut ∼ T )→< Mol > + · · · < auto rate >
Remark: The molecules on the right-hand side of this type of rules will be released into
the microenvironment due to autophagy. They are the existing molecules expressed
inside this cell when autophagy is triggered.
Rule 5: Secretion
< Cell > (< secMol >∼ T )→< Cell > (< secMol >∼ F)+ < Mol > < sec rate >
Remark: When the secretion of “< Mol >” has been triggered, its amount in the mi-
croenvironment will be added by 1. Note that, we can differentiate the endogenous and
exogenous molecules by labeling the secreted “< Mol >” with the cell name. In our
model, we have “PCC(secEGF ∼ T )→ PCC(secEGF ∼ F) + EGF 2.7e − 4”.
Rule 6: Mutation
< Cell > (< Mol >∼< unmutated >)→< Cell > (< Mol >∼< mutated >) < mrate >
Remark: For mutant proteins that are constitutively active, we set a very high value to
the mutation rate “mrate”. In this way, we can almost keep the value of the mutated
molecule as what it should be. For example, in our model, the mutation of oncoprotein
Ras in PCCs is captured by “PCC(RAS ∼ F)→ PCC(RAS ∼ T ) 10000”.
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Rule 7: Constantly over-expressed extracellular molecules
CancerEvn→ CancerEvn+ < Mol > < sec rate >
Remark: We use this type of rules to mimic the situation that the concentration of an
over-expressed extracellular molecule stays in a high level constantly.
Rule 8: Degradation of extracellular molecules
< Mol >→ Null() < deg rate >
Remark: Here, “Null()” is used to represent dead cells or degraded molecules. For in-
stance, bFGF in the microenvironment will be degraded via “bFGF → Null() 0.05”.
Rule 9: Therapeutic intervention
< Cell > (< Mol >∼< untreated >)→< Cell > (< Mol >∼< treated >) < treat rate >
Remark: Given a validated model, intervention rules allow us to evaluate the effective-
ness of a therapy targeting at certain molecule(s). Also, the well-tuned value of the
intervention rate can, more or less, give indications when deciding the dose of medicine
used in this therapy, based on the Law of Mass Action.
Our extension allows the BioNetGen language to be able to model not only the
signaling network within a single cell, but also interactions among multiple cells. It
also allows one to simulate the dynamics of cell populations, which is crucial to cancer
study. Moreover, describing the intracellular dynamics using the style of BNs improves
the scalability of our method by overcoming the difficulty of obtaining values of a large
amount of model parameters from wet laboratory, which is a common bottleneck of
conventional rule-based languages and ML-Rules. Note that, similar to other rule-based
languages, our extended one allows different methods for model analysis, since more
than one semantics can be defined for the same syntax.
4 Statistical Model Checking
Simulation can recapitulate a number of experimental observations and provide new in-
sights into the system. However, it is not easy to manually analyze a significant amount
of simulation trajectories, especially when there is a large set of system properties to be
tested. Thus, for our model, we employ statistical model checking (StatMC), which is a
fully automated formal analysis technique. In this section, we provide an intuitive and
brief description of StatMC. The interested reader can find more details in [22].
Given a system property expressed as a Bounded Linear Temporal Logic (BLTL)
[22] formula and the set of simulation trajectories generated by applying the NFsim
stochastic simulation to our rule-based model, StatMC estimates the probability of the
model satisfying the property. (See Appendix A for a brief introduction of BLTL.) In
detail, since the underlying semantic model of the stochastic simulation method NFsim
that we used for our model is essentially a discrete-time Markov chain, we need to ver-
ify stochastic models. StatMC treats the verification problem for stochastic models as
a statistical inference problem, using randomized sampling to generate traces (or sim-
ulation trajectories) from the system model, and then performing model checking and
statistical analysis on those traces. For a (closed) stochastic model and a BLTL property
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ψ, the probability p that the model satisfies ψ is well defined (but unknown in general).
For a fixed 0 < θ < 1, we ask whether p ≤ θ, or what the value of p is. In StatMC,
the first question is solved via hypothesis testing methods, while the second via esti-
mation techniques. Intuitively, hypothesis tests are probabilistic decision procedures,
i.e., algorithms with a yes/no reply, and which may give wrong answers. Estimation
techniques instead compute (probabilistic) approximations of the unknown probability
p. The main assumption of StatMC is that, given a BLTL property ψ, the behavior of a
(closed) stochastic model can be described by a Bernoulli random variable of parameter
p, where p is the probability that the system satisfies ψ. It is known that discrete-time
Markov chains satisfy this requirement [36]. Therefore StatMC can be applied to our
setting. More specifically, given σ is a system execution and ψ a BLTL formula, we
have that Prob{σ|σ |= ψ} = p, and the Bernoulli random variable mentioned above
is the following function M defined as follows: M(σ) = 1 if σ |= ψ, or M(σ) = 0
otherwise. Therefore, M will be 1 with probability p and 0 with probability 1 − p. In
general, StatMC works by first obtaining samples of M, and then by applying statistical
techniques to such samples to solve the verification problem.
5 Results and Discussion
In this section, we present and discuss formal analysis results for our pancreatic cancer
microenvironment model. The model file is available at http://www.cs.cmu.edu/
˜qinsiw/mpc_model.bngl. All the experiments reported below were conducted on
a machine with a 1.7 GHz Intel Core i7 processor and 8GBRAM, running on Ubuntu
14.04.1 LTS. In our experiments, we use Bayesian sequential estimation with 0.01 as
the estimation error bound, coverage probability 0.99, and a uniform prior (α = β = 1).
The time bounds and thresholds given in following properties are determined by consid-
ering the model’s simulation results. The parameters in our model include initial state
(e.g. abundance of extracellular molecules) and reaction rate constants. The initial state
was provided by biologists based on wet-lab measurements. The rate constants were
estimated based on the general ones in the textbook [4]. The results in scenario I & II
demonstrate that using these parameters the model is able to reproduce key observa-
tions reported in the literature. We also performed a sensitivity analysis and the results
show that the system behavior is robust to most of the parameters (the two sensitive
parameters have been labeled in our model file).
Scenario I: mutated PCCs with no treatments
In scenario I, we validate our model by studying the role of PSCs in the PC devel-
opment.
Property 1: This property aims to estimate the probability that the population of PCCs
will eventually reach and maintain in a high level.
Prob=? {(PCCtot = 10) ∧ F1200 G100 (PCCtot > 200)}
First, we take a look at the impact from the presence of PSCs on the dynamics of PCC
population. As shown in Table 1, with PSCs, the probability of the number of PCCs
reaching and keeping in a high level (Pr = 0.9961) is much higher than the one when
PSCs are absent (Pr = 0.405). This indicates that PSCs promote PCCs proliferation
during the progression of PC. This is consistent with experimental findings [6, 10, 38].
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Property Estimated Prob # Succ # Sample Time (s) Note
Scenario I: mutated PCCs with no treatments
1 0.4053 10585 26112 208.91 w.o. PSCs
0.9961 256 256 1.83 w. PSCs
2 0.1191 830 6976 49.69 w.o. PCCs
0.9961 256 256 1.75 w. PCCs
3 0.9961 256 256 5.21 -
4 0.9961 256 256 4.38 -
Scenario II: mutated PCCs with different exsiting treatments
5 0.0004 0 2304 17.13 cetuximab and erlotinib
0.0012 10 9152 68.67 gemcitabine
0.7810 8873 11360 114.25 nab-paclitaxel
0.8004 7753 9686 73.83 ruxolitinib
Scenario III: mutated PCCs with blocking out on possible target(s)
6 0.0792 38363 484128 3727.99 w.o. inhibiting ERK in PSCs
0.9822 2201 2240 17.37 w. inhibiting ERK in PSCs
7 0.1979 3409 17232 136.39 w.o. inhibiting ERK in PSCs
0.9961 256 256 2.01 w. inhibiting ERK in PSCs
8 0.2029 2181 10752 92.57 w.o. inhibiting MDM2 in PSCs
0.9961 256 256 2.18 w. inhibiting MDM2 in PSCs
9 0.0004 0 2304 15.77 w.o. inhibiting RAS in PCCs and
ERK in PSCs
0.9961 256 256 3.15 w. inhibiting RAS in PCCs and
ERK in PSCs
10 0.9797 1349 1376 11.98 w.o. inhibiting STAT in PCCs and
NFκB in PSCs
0.1631 1476 9056 81.61 w. inhibiting STAT in PCCs and
NFκB in PSCs
Table 1: Statistical model checking results for properties under different scenarios
Property 2: This property aims to estimate the probability that the number of migrated
PSCs will eventually reach and maintain in a high amount.
Prob=? {(MigPSC = 0) ∧ F1200 G100 (MigPSC > 40)}
We then study the impacts from PCCs on PSCs. As shown in Table 1, without PCCs, it
is quite unlikely ((Pr = 0.1191) for quiescent PSCs to be activated. While, when PCCs
exist, the chance of PSCs becoming active ((Pr = 0.9961) approaches to 1. This con-
firms the observation [18] that, during the development of PC, PSCs will be activated
by growth factors, cytokines, and oxidant stress secreted or induced by PCCs.
Property 3: This property aims to estimate the probability that the number of PCCs en-
tering the apoptosis phase will be larger than the number of PCCs starting the autophagy
process and this situation will be reversed eventually.
Prob=? {F400 (G300 (ApoPCC > 50 ∧ AutoPCC < 50)
∧F700 G300 (ApoPCC < 50 ∧ AutoPCC > 50))}
We are also interested in the mutually exclusive relationship between apoptosis and au-
tophagy for PCCs reported in [19,26]. In detail, as PC progresses, apoptosis firstly over-
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whelms autophagy, and then autophagy takes the leading place after a certain amount
of time. This situation is described as property 3 and its estimated probability is close
to 1 (see Table 1).
Property 4: This property aims to estimate the probability that, it is always the case
that, once the population of activated PSCs reaches a high level, the number of migrated
PSCs will also increase.
Prob=? {G1600 (ActPSC > 10→ F100 (MigPSC > 10))}
One reason why PC is hard to be cured is that activated PSCs will move towards mutated
PCCs, and form a cocoon for the tumor cells, which can protect tumor from attacks
caused by therapies [6, 14]. We investigate this by checking property 4, and obtain an
estimated probability approaching to 1 (see Table 1).
Scenario II: mutated PCCs with different existing treatments
Property 5: This property aims to estimate the probability that the population of PCCs
will eventually drop to and maintain in a low amount.
Prob=? {(PCCtot = 10) ∧ F1200 G400 (PCCtot < 100)}
Property 5 means that, after some time, the population of PCCs can be maintained in a
comparatively low amount, implying that PC is under control. We now consider 5 dif-
ferent drugs that are widely used in PC treatments - cetuximab, erlotinib, gemcitabine,
nab-paclitaxel, and ruxolitinib, and estimate the probabilities for them to satisfy prop-
erty 5. As shown in Table 1, monoclonal antibody targeting EGFR (cetuximab), as well
as direct inhibition of EGFR (erlotinib) broadly do not provide a survival benefit in
PCs. Inhibition of MAPK pathway (gemcitabine) has also not been promising. These
results are consistent with clinical feedbacks from patients [1]. While, strategies aiming
at depleting the PSCs in PCs (i.e. nab-paclitaxel) can be successful (with an estimated
probability 0.7810). Also, inhibition of Jak/Stat can be very promising (with an esti-
mated probability 0.8004). These results are supported by [37] and [20], respectively.
Scenario III: mutated PCCs with blocking out on possible target(s)
Scenario I and II have demonstrated the descriptive and predictive power of our
model. In scenario III, we use the validated model to identify new therapeutic strategies
targeting molecules in PSCs. Here we report 4 potential target(s) of interest from our
screening.
Property 6: This property aims to estimate the probability that the number of PSCs will
eventually drop to and maintain in a low level.
Prob=? {(PSCtot = 5) ∧ F1200 G400 (PSCtot < 30)}
Property 7: This property aims to estimate the probability that the population of mi-
grated PSCs will eventually stay in a low amount.
Prob=? {(MigPSC = 0) ∧ F1200 G100 (MigPSC < 30)}
The verification results of these two properties (Table 1) suggest that inhibiting ERK in
PSCs not only lowers the population of PSCs, but also inhibits PSC migration. The for-
mer function can reduce the assistance from PSCs in the progression of PCs indirectly.
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The later one can prevent PSCs from moving towards PCCs and forming a cocoon to
protect PCCs against cancer treatments.
Property 8: This property aims to estimate the probability that the number of PSCs
entering the proliferation phase will eventually be less than the number of PSCs starting
the apoptosis programme and this situation will maintain.
Prob=? {F1200 G400 ((PSCPro − PSCApop) < 0)}
The increased probability (from 0.2029 to 0.9961 as shown in Table 1) indicates that
inhibiting MDM2 in PSCs may reduce the number of PSCs by inhibiting PSCs’ prolif-
eration and/or promoting their apoptosis. Similar to the former role of inhibiting ERK
in PSCs, it can help to treat PCs by alleviating the burden caused by PSCs.
Property 9: This property aims to estimate the probability that the number of bFGF
will eventually stay in such a low level.
Prob=? {F1200 G400 (bFGF < 100)}
As mentioned in property 5, 6, and 7, inhibiting RAS in PCCs can lower the number of
PCCs, and downregulating ERK in PSCs can inhibit their proliferation and migration.
Besides these, we find that, when inhibiting RAS in PCCs and ERK in PSCs simulta-
neously, the concentration of bFGF in the microenvironment drops (see Table 1). As
bFGF is a key molecule that induces proliferation of both cell types, targeting RAS in
PCCs and ERK in PSCs at the same time could synergistically improve PC treatment.
Property 10: This property aims to estimate the probability that the concentration of
VEGF will eventually reach and keep in a high level.
Prob=? {F400 G100 (VEGF > 200)}
Furthermore, inhibiting STAT in PCCs and NFκB in PSCs simultaneously postpones
and lowers the secretion of VEGF (see Table 1). VEGF plays an important role in the
angiogenesis and metastasis of pancreatic tumors. Thus, the combinatory inhibition of
STAT in PCCs and NFκB in PSCs may be another potential strategy for PC therapies.
6 Conclusion
We present a multicellular and multiscale model of the PC microenvironment. The
model is formally described using the extended BioNetGen language, which enables
us to capture the dynamics of multiscale biological systems using a combination of
continuous and discrete rules. We carry out stochastic simulation and StatMC to ana-
lyze system behaviors under diffident conditions. Our verification results confirm the
experimental findings with regard to the mutual promotion between PCCs and PSCs.
We also gain insights on how existing treatments latching onto different targets can
lead to distinct outcomes. These results demonstrate that our model could be used as
a prognostic platform to identify new drug targets. We then identify four potentially
(poly)pharmacological strategies for depleting PSCs and inhibiting the PC develop-
ment. We plan to test our predictions empirically in future. Another interesting direction
is to extend the model by taking account of cancer-associated macrophages in the PC
microenvironment.
14 Q. Wang et al.
References
1. Personal communication with Jeffrey M Clarke, MD (Duke University School of Medicine).
2. World Cancer Report 2014, World Health Organization, 2014.
3. R. Albert and J. Thakar. Boolean modeling: a logic-based dynamic approach for understand-
ing signaling and regulatory networks and for making useful predictions. Wiley Interdisci-
plinary Reviews: Systems Biology and Medicine, 6(5):353–369, 2014.
4. U. Alon. An introduction to systems biology: design principles of biological circuits. CRC
press, 2006.
5. P. M. Altrock, L. L. Liu, and F. Michor. The mathematics of cancer: integrating quantitative
models. Nature Reviews Cancer, 15(12):730–745, 2015.
6. M. Apte, S. Park, P. Phillips, N. Santucci, D. Goldstein, R. Kumar, G. Ramm, M. Buchler,
H. Friess, J. McCarroll, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic
stellate cells. Pancreas, 29(3):179–187, 2004.
7. N. Bardeesy and R. A. DePinho. Pancreatic cancer biology and genetics. Nature Reviews
Cancer, 2(12):897–909, 2002.
8. M. Bensaid, N. Tahiri-Jouti, C. Cambillau, N. Viguerie, B. Colas, C. Vidal, J. Tauber, J. Es-
teve, C. Susini, and N. Vaysse. Basic fibroblast growth factor induces proliferation of a
rat pancreatic cancer cell line. Inhibition by somatostatin. International Journal of Cancer,
50(5):796–799, 1992.
9. V. Danos, J. Feret, W. Fontana, R. Harmer, and J. Krivine. Rule-based modelling of cellular
signalling. In CONCUR 2007–Concurrency Theory, pages 17–41. Springer, 2007.
10. S. Dune´r, J. L. Lindman, D. Ansari, C. Gundewar, and R. Andersson. Pancreatic cancer: the
role of pancreatic stellate cells in tumor progression. Pancreatology, 10(6):673–681, 2011.
11. M. Erkan, C. Reiser-Erkan, C. Michalski, and J. Kleeff. Tumor microenvironment and pro-
gression of pancreatic cancer. Experimental Oncology, 32(3):128–131, 2010.
12. J. R. Faeder, M. L. Blinov, and W. S. Hlavacek. Rule-based modeling of biochemical systems
with bionetgen. In Systems Biology, pages 113–167. Springer, 2009.
13. B. Farrow, D. Albo, and D. H. Berger. The role of the tumor microenvironment in the
progression of pancreatic cancer. Journal of Surgical Research, 149(2):319–328, 2008.
14. C. Feig, A. Gopinathan, A. Neesse, D. S. Chan, N. Cook, and D. A. Tuveson. The pancreas
cancer microenvironment. Clinical Cancer Research, 18(16):4266–4276, 2012.
15. H. Gong. Analysis of intercellular signal transduction in the tumor microenvironment. BMC
Systems Biology, 7(Suppl 3):S5, 2013.
16. H. Gong, Q. Wang, P. Zuliani, J. R. Faeder, M. Lotze, and E. Clarke. Symbolic model
checking of signaling pathways in pancreatic cancer. In 3rd International Conference on
Bioinformatics and Computational Biology, page 245, 2011.
17. H. Gong, P. Zuliani, Q. Wang, and E. M. Clarke. Formal analysis for logical models of
pancreatic cancer. In 50th IEEE Conference on Decision and Control and European Control
Conference, pages 4855–4860, 2011.
18. P. S. Haber, G. W. Keogh, M. V. Apte, C. S. Moran, N. L. Stewart, D. H. Crawford, R. C.
Pirola, G. W. McCaughan, G. A. Ramm, and J. S. Wilson. Activation of pancreatic stellate
cells in human and experimental pancreatic fibrosis. The American Journal of Pathology,
155(4):1087–1095, 1999.
19. M. M. Hippert, P. S. O’Toole, and A. Thorburn. Autophagy in cancer: good, bad, or both?
Cancer Research, 66(19):9349–9351, 2006.
20. H. Hurwitz, N. Uppal, S. Wagner, J. Bendell, J. Beck, S. Wade, J. Nemunaitis, P. Stella,
J. Pipas, Z. Wainberg, et al. A randomized double-blind phase 2 study of ruxolitinib (RUX)
or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with
metastatic pancreatic cancer (mPC). Journal of Clinical Oncology, 32:55, 2014.
Formal Modeling and Analysis of Pancreatic Cancer Microenvironment 15
21. R. Jaster. Molecular regulation of pancreatic stellate cell function. Molecular Cancer,
3(1):26, 2004.
22. S. K. Jha, E. M. Clarke, C. J. Langmead, A. Legay, A. Platzer, and P. Zuliani. A Bayesian
approach to model checking biological systems. In Computational Methods in Systems Bi-
ology, pages 218–234. Springer, 2009.
23. J. Kleeff, P. Beckhove, I. Esposito, S. Herzig, P. E. Huber, J. M. Lo¨hr, and H. Friess. Pancre-
atic cancer microenvironment. International Journal of Cancer, 121(4):699–705, 2007.
24. Y. Kondo, T. Kanzawa, R. Sawaya, and S. Kondo. The role of autophagy in cancer develop-
ment and response to therapy. Nature Reviews Cancer, 5(9):726–734, 2005.
25. D. Mahadevan and D. D. Von Hoff. Tumor-stroma interactions in pancreatic ductal adeno-
carcinoma. Molecular Cancer Therapeutics, 6(4):1186–1197, 2007.
26. G. Marin˜o, M. Niso-Santano, E. H. Baehrecke, and G. Kroemer. Self-consumption: the
interplay of autophagy and apoptosis. Nature Reviews: Molecular Cell Biology, 15(2):81–
94, 2014.
27. A. Masamune, M. Satoh, K. Kikuta, N. Suzuki, K. Satoh, and T. Shimosegawa. Ellagic acid
blocks activation of pancreatic stellate cells. Biochemical Pharmacology, 70(6):869–878,
2005.
28. C. Maus, S. Rybacki, and A. M. Uhrmacher. Rule-based multi-level modeling of cell bio-
logical systems. BMC Systems Biology, 5(1):166, 2011.
29. D. Muilenburg, C. Parsons, J. Coates, S. Virudachalam, and R. J. Bold. Role of autophagy
in apoptotic regulation by Akt in pancreatic cancer. Anticancer Research, 34(2):631–637,
2014.
30. L. Murphy, M. Cluck, S. Lovas, F. O¨tvo¨s, R. Murphy, A. Schally, J. Permert, J. Lars-
son, J. Knezetic, and T. Adrian. Pancreatic cancer cells require an EGF receptor-mediated
autocrine pathway for proliferation in serum-free conditions. British Journal of Cancer,
84(7):926, 2001.
31. P. Phillips, M. Wu, R. Kumar, E. Doherty, J. McCarroll, S. Park, R. C. Pirola, J. Wilson, and
M. Apte. Cell migration: a novel aspect of pancreatic stellate cell biology. Gut, 52(5):677–
682, 2003.
32. A. Pnueli. The temporal logic of programs. In IEEE 18th Annual Symposium on Foundations
of Computer Science, pages 46–57, 1977.
33. P. M. Siegel and J. Massague´. Cytostatic and apoptotic actions of TGF-β in homeostasis and
cancer. Nature Reviews Cancer, 3(11):807–820, 2003.
34. M. W. Sneddon, J. R. Faeder, and T. Emonet. Efficient modeling, simulation and coarse-
graining of biological complexity with nfsim. Nature Methods, 8(2):177–183, 2011.
35. R. Thomas, D. Thieffry, and M. Kaufman. Dynamical behaviour of biological regulatory
networks - I. Biological role of feedback loops and practical use of the concept of the loop-
characteristic state. Bulletin of Mathematical Biology, 57(2):247–276, 1995.
36. M. Y. Vardi. Automatic verification of probabilistic concurrent finite state programs. In IEEE
26th Annual Symposium on Foundations of Computer Science, pages 327–338, 1985.
37. D. D. Von Hoff, T. Ervin, F. P. Arena, E. G. Chiorean, J. Infante, M. Moore, T. Seay, S. A.
Tjulandin, W. W. Ma, M. N. Saleh, et al. Increased survival in pancreatic cancer with nab-
paclitaxel plus gemcitabine. New England Journal of Medicine, 369(18):1691–1703, 2013.
38. A. Vonlaufen, S. Joshi, C. Qu, P. A. Phillips, Z. Xu, N. R. Parker, C. S. Toi, R. C. Pirola, J. S.
Wilson, D. Goldstein, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer
cells. Cancer Research, 68(7):2085–2093, 2008.
16 Q. Wang et al.
A Bounded Linear Temporal Logic
In this appendix, we will briefly review Bounded LTL that we use to encode system
properties in the “Results and Discussion” section.
Linear Temporal Logic (LTL) [32], as a modal temporal logic with modalities refer-
ring to time, is widely used to formally encode formulae about the future of paths, such
as a condition will eventually be true or a condition will be true until another fact be-
comes true. Bounded Linear Temporal Logic (BLTL) extends LTL with time bounds on
temporal operators. For example, the following BLTL formula can be used to express
the specification it is not the case that within 5 seconds, variable v0 will keep the value
1 and variable v1 will keep the value 0 for 10 seconds.
¬F5G10(v0 = 1 ∧ v1 = 0)
where the F5 operator encodes future 5 seconds, G10 expresses globally for 10 seconds,
and v0 and v1 are state variables of the model.
The syntax of BLTL is given by:
ψ ::= x ∼ v|¬ψ|ψ1 ∨ ψ2|ψ1U tψ2
where x ∈ SV (the finite set of state variables), ∼∈ {<,≤,=,≥, >}, v ∈ Q, and t ∈ Q≥0.
Note that the operators ∧, F t, and Gt referenced above can be defined as follows: F tψ =
True U tψ, Gtψ = ¬F t¬ψ, and ψ1 ∧ ψ2 = ¬(¬ψ1 ∨ ¬ψ2)
The semantics of BLTL is defined with respect to traces (or executions) of the
model. For this work, a trace will be a simulation trajectory of our multiscale hybrid
rule-based model. Formally, a trace is a sequence of time-stamped state transitions of
the form σ = (s0, t0), (s1, t1), · · · , indicating that the system moved to state si+1 after
duration ti in state si. The fact that a trace σ satisfies the BLTL property ψ is denoted
by s |= ψ. We denote the execution trace starting at state i by σi. The value of the state
variable x in σ at the state i is denoted by V(σ, i, x). The semantics of BLTL for a trace
σk starting at the kth state (k ∈ N) is defined as follows.
– σk |= x ∼ v if and only if V(σ, i, x) ∼ v;
– σk |= ¬ψ if and only if σk |= ψ does not hold;
– σk |= ψ1 ∨ ψ2 if and only if σk |= ψ1 or σk |= ψ2;
– σk |= ψ1U tψ2 if and only if there exists i ∈ N+ such that (a) ∑k+i−1j=k t j ≤ t, (b)
σk+i |= ψ2, and (c) for each 0 ≤ j < i, σk+ j |= ψ1.
